Treatment Options For Global Gastric Cancer Market: Surgery, Chemotherapy, Radiotherapy And Targeted Therapy

Researchmoz added Most up-to-date research on "Treatment Options For Global Gastric Cancer Market: Surgery, Chemotherapy, Radiotherapy And Targeted Therapy" to its huge collection of research reports.

Cancer is a condition where an error or mutation in the cell’s DNA occurs, causing it to grow at a rapid rate. A cancer cell continues living while a normal cell would die, thus, accumulating to form a tumor that can break off and spread throughout the body. Gastric cancer is when such a condition occurs in the stomach and has the tendency to grow through the wall of the stomach to invade nearby organs including lymph nodes and lymph vessels. There are four types of cancers of the stomach namely, Adenocarcinoma, Lymphoma, Gastrointestinal stromal tumor (GIST), Carcinoid tumor and others such as squamous cell carcinoma, small cell carcinoma, and leiomyosarcomat that can start in the stomach, but are very rare.

The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=728193

Global gastric cancer market is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.

The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.

Browse TOC @ https://www.researchmoz.us/global-gastric-cancer-market-report-2016-edition-report.html/toc

Table of Content

1. Market Overview
1.1 Introduction
1.2 Types  
1.3 Stages  
1.4 Causes & Prevention  
1.5 Diagnosis  
1.5.1 Symptoms  
1.5.2 Medical Diagnosis  
1.6 Treatment Options  
1.6.1 Surgery  
1.6.2 Chemotherapy  
1.6.3 Radiotherapy  
1.6.4 Targeted Therapy

2. Global Market
2.1 Global Gastric Cancer Market by Prevalence
2.2 Global Advanced Gastric Cancer Market by Value

3. Regional Markets
3.1. The U.S.  
3.1.1 The U.S. Gastric Cancer Market by Prevalence  
3.1.2 The U.S. Her 2+ Gastric Cancer Prevalence  
3.1.3 The U.S. Stage III Gastric Cancer Prevalence  
3.1.4 The U.S. Advanced Gastric Cancer Market by Prevalence  
3.1.5 The U.S. Advanced Gastric Cancer Market by Value  
3.1.6 The U.S. Metastatic Gastric Cancer Prevalence

Treatment Options Available For Global Gastric Cancer Market: Surgery, Chemotherapy, Radiotherapy And Targeted Therapy

Researchmoz added Most up-to-date research on "Treatment Options Available For Global Gastric Cancer Market: Surgery, Chemotherapy, Radiotherapy And Targeted Therapy" to its huge collection of research reports.

Cancer is a condition where an error or mutation in the cell’s DNA occurs, causing it to grow at a rapid rate. A cancer cell continues living while a normal cell would die, thus, accumulating to form a tumor that can break off and spread throughout the body. Gastric cancer is when such a condition occurs in the stomach and has the tendency to grow through the wall of the stomach to invade nearby organs including lymph nodes and lymph vessels. There are four types of cancers of the stomach namely, Adenocarcinoma, Lymphoma, Gastrointestinal stromal tumor (GIST), Carcinoid tumor and others such as squamous cell carcinoma, small cell carcinoma, and leiomyosarcomat that can start in the stomach, but are very rare.

The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.

Global gastric cancer market is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=728193

The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.

Table of Content

1. Market Overview
1.1 Introduction
1.2 Types  
1.3 Stages  
1.4 Causes & Prevention  
1.5 Diagnosis  
1.5.1 Symptoms  
1.5.2 Medical Diagnosis  
1.6 Treatment Options  
1.6.1 Surgery  
1.6.2 Chemotherapy  
1.6.3 Radiotherapy  
1.6.4 Targeted Therapy

2. Global Market
2.1 Global Gastric Cancer Market by Prevalence
2.2 Global Advanced Gastric Cancer Market by Value

3. Regional Markets
3.1. The U.S.  
3.1.1 The U.S. Gastric Cancer Market by Prevalence  
3.1.2 The U.S. Her 2+ Gastric Cancer Prevalence  
3.1.3 The U.S. Stage III Gastric Cancer Prevalence  
3.1.4 The U.S. Advanced Gastric Cancer Market by Prevalence  
3.1.5 The U.S. Advanced Gastric Cancer Market by Value

Browse More Details @ http://www.researchmoz.us/global-gastric-cancer-market-report-2016-edition-report.html

Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs | Frontier Pharma

Researchmoz added Most up-to-date research on "Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs | Frontier Pharma" to its huge collection of research reports.

Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Scope

• What is the pathophysiology of gastric cancer?
• How is gastric cancer diagnosed?
• What are the current treatment options?
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
• What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=713902

• What are the most promising first-in-class targets for gastric cancer?
• Will the current first-in-class targets have a broader therapeutic potential across the industry?
• How do deal frequency and value compare between target families and molecule types?
• How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
• Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
• Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=713902